Investors

Martin Sutter has served as a member of our board of directors since April 2004 and was appointed Lead Director in August 2007. Since 1988, Mr. Sutter has served as Managing Director of Essex Woodlands Health Ventures, a venture capital partnership focused on healthcare investments and previously served as a Managing Director of one of its predecessors. Mr. Sutter serves as a member of the board of directors of LifeCell, a publicly-traded biotechnology company, and La Jolla Pharmaceutical, a publiclytraded biopharmaceutical company. He currently serves on the board of directors of several privatelyheld life science companies. Mr. Sutter holds a B.S. from Louisiana State University and an M.B.A. from the University of Houston.

Albert Cha, M.D., Ph.D. has served as a member of our board of directors since June 2002. In 2000, Dr. Cha joined Vivo Ventures, a life science venture capital firm, where he has served in various positions, most recently as a Managing Partner. Dr. Cha currently serves on the board of directors of BioDel, a publicly-traded development stage pharmaceutical company. He currently serves as a member of the board of directors of several privately-held biotechnology and medical device companies. Dr. Cha holds a B.S. and an M.S. from Stanford University and an M.D. and a Ph.D. from the University of California at Los Angeles.

Tim Lynch has served as a member of our board of directors since July 2006. Since October 2005, Mr. Lynch has served as President and Chief Executive Officer of NeuroStat Pharmaceuticals, a specialty pharmaceutical company. From June 2005 through September 2005, Mr. Lynch was President and Chief Executive Officer of Vivo Therapeutics, a specialty pharmaceuticals company. From October 2002 through June 2005, Mr. Lynch served as Chief Financial Officer of Tercica, a publicly-traded biopharmaceutical company. From 1999 to June 2002, Mr. Lynch served as Chief Financial Officer of InterMune, a publicly-traded biopharmaceutical company. Currently, Mr. Lynch serves as a member of the board of directors of both Nabi Biopharmaceuticals, a publicly-traded biopharmaceutical company, and Allos Therapeutics, a publicly-traded biotechnology company. Mr. Lynch holds a B.A. from Colgate University and an M.B.A. from the Harvard Graduate School of Business.

Kevin Sidow has served as a member of our board of directors since July 2007. Mr. Sidow served as President and Chief Executive Officer and as a member of the board of directors of St. Francis Medical Technologies from May 2004 until the company was acquired by Kyphon, a publicly-traded orthopedic company, in January 2007. From 1998 to May 2004, Mr. Sidow held a number of executive positions with DePuy, a subsidiary of Johnson & Johnson and a designer, manufacturer and distributor of medical devices. From October 2003 to May 2004, he was Worldwide President of DePuy, and from March 2001 to October 2003, he served as Worldwide President of DePuy Orthopaedics, ACE and Casting. Mr. Sidow holds a B.S. from West Virginia University.